Tue, Jul 29, 2014, 9:44 AM EDT - U.S. Markets close in 6 hrs 16 mins

Recent

% | $
Click the to save as a favorite.

Roche Holding AG Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Predicts Sierra World Equity Review

    Sentiment: Strong Buy

  • Reply to

    is roche going to partner with mannkind

    by charles_lacy2003 Jun 27, 2014 5:53 PM

    Roche And MannKind (MNKD) News To Lead Top Stock News This Week Predicts Sierra World Equity Review
    HEADLINE: Roche And MannKind (MNKD) News To Lead Top Stock News This Week Predicts Sierra World Equity Review.

    Sentiment: Strong Buy

  • Roche (RHHBY) has a broad portfolio of diagnostic tests with more than a hundred high-quality Elecsys assays for immune testing along with a new generation of fully automated cobas analyzers for improved medical decision making, scheduling and efficiency.

    The company is striving hard to further strengthen its Diagnostics division. Roche recently received positive news when Health Canada approved its cobas 800 HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women aged 25 years and above.

    Additionally, Roche launched its fully automated CINtecPLUS test in Canada, which enables improved detection and early intervention of pre-cancerous cervical disease. The launch of the cytology test in Canada will help identify women with high-grade pre-cancerous cervical lesions who need immediate colposcopy.

    Roche's cobas 4800 HPV Test will provide both pooled high-risk HPV DNA results and individual detection of HPV 16 and HPV 18, which cause approximately 70% of cervical cancer. The approval was based on encouraging results from the ATHENA trial wherein it was observed that one in four women who are HPV 16 positive will have cervical disease within three years and that nearly one in seven women with normal Pap cytology who were HPV 16 positive suffered from high-grade cervical disease that was missed by cytology.

    We remind investors that in Apr 2014, the FDA also approved Roche's cobas HPV Test for use as a first-line primary screening test for cervical cancer in women aged 25 years and above.

    We are impressed by Roche’s efforts to strengthen its Diagnostic Division. The Diagnostics Division generated sales of $10.5 billion in 2013, up 4% from a year ago. The approval of new tests will further boost the sales of this division.

    Sentiment: Strong Buy

  • Reply to

    Roche is king

    by amgnjim Jun 2, 2014 9:55 AM

    Roche lost out on ILMN.

  • Health Canada Approves Roche's HPV Test for First-Line Primary Screening of Cervical Cancer and Roche Launches New Cytology Test to Provide the Most Comprehensive Portfolio for Cervical Cancer ScreeningLAVAL, QC, June 10, 2014 /CNW Telbec/ - Roche announced that Health Canada approved the cobas® 4800 HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical cancer in women 25 and older. Roche has also launched the fully automated CINtec® PLUS test to improve the detection and early intervention of pre-cancerous cervical disease. The Health Canada approved CINtec® PLUS cytology test helps identify women with high-grade pre-cancerous cervical lesions who need immediate colposcopy. Roche's portfolio of cervical cancer screening products provides the most comprehensive strategies for cervical cancer prevention and treatment.

    "We are very pleased that Health Canada has approved the cobas® 4800 HPV test for use as a first-line primary screening test to identify women at increased risk for the development of cervical cancer", said Ian Parfrement, President & General Manager, Roche Diagnostics Canada. "We will partner with healthcare professionals and authorities to redefine and adapt current practice guidelines to encourage clinicians to incorporate these new tests in their patient protocols. If caught early, cervical cancer is one of the most preventable and curable cancers with a survival rate of more than 90% and with our Cervical Cancer Screening solution we will certainly improve patient care and people's health."

    "Canada has always been on the forefront of innovative strategies in cervical cancer prevention," said Dr. Eduardo Franco, James McGill Professor and Chair, Department of Oncology, Director, Division of Cancer Epidemiology, McGill University. "Once again, Canadian women will benefit from a major technological innovation, with the recent approval by Health Canada of the first molecular test with genotyping 16 & 18 for general cervical cancer screening. The new indication will give women more safety while reducing their dependence on frequent screening visits."

    The cobas® 4800 HPV Test provides both pooled high-risk HPV DNA results and individual detection of HPV 16 and HPV 18, the two types responsible for about 70 percent of cervical cancer. Health Canada's decision to approve the expanded use for the cobas® 4800 HPV Test was based on results from the landmark ATHENA trial, which enrolled more than 47,000 women. The study demonstrated that one in four women who are HPV 16 positive will have cervical disease within three years and that nearly 1 in 7 women with normal Pap cytology who were HPV 16 positive actually had high-grade cervical disease that was missed by cytology.

    In addition, results from the ATHENA trial included a comparison of a cobas® 4800 HPV Test screening strategy to alternative strategies using Pap cytology and HPV testing. The comparison showed that a strategy leveraging the ability of the cobas® 4800 HPV Test to identify women testing positive for HPV 16 or 18, and using cervical cytology as a triage, follow-up test, would allow clinicians to detect more disease without referring a significant number of women to unnecessary follow-up.

    Sentiment: Strong Buy

  • Roche's (RHHBY) Ventana Medical Systems, Inc. has entered into a collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca (AZN).

    Both the companies are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune's MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. The deal includes the MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.

    The treatment is based on cancer immunotherapy which is gaining a lot of interest in the recent times as pharmaceuticals majors focus their R&D efforts on the same.

    Roche specializes in cancer drugs. We are encouraged by the recent bout of news on the pipeline candidates. Last week, Roche announced positive results from a phase I study on oncology candidate, anti-PDL1 (MPDL3280A).

    The results from the study showed that immunotherapy candidate MPDL3280A was effective in shrinking tumors by 43% in treatment experienced patients suffering from metastatic urothelial bladder cancer. These patients had tumors that were characterized as PD-L1 positive by a test being developed by Roche. The candidate was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (:FDA).

    On the other hand, Roche recently announced encouraging results from a phase II study, JO25567. The study evaluated the safety and efficacy of Avastin in combination with Tarceva as the first line treatment for patients suffering from advanced non-small cell lung cancer (:NSCLC) characterized by activating mutations of the epidermal growth factor receptor (EGFR Mut+) compared to Tarceva alone.

    The study was conducted in Japan. The results from the study showed that Avastin in combination with Tarceva helped patients live significantly longer without their disease getting worse compared to those given Tarceva alone. Consequently, the study met its primary endpoint of progression-free survival (PFS). Both the drugs are already approved for the treatment of lung cancer.

    Sentiment: Buy

  • When Roche bought Gen. and Amgn was $19 per. share, Roche was buying bio , others were ###their #$%$

    Sentiment: Strong Buy

  • starting , get in, its all about making money

  • Was just reading thur abstracts for todays ASGCT presentations and found Dr. heller time is listed as 6:15pm to 8:15 pm. I have not been able to find a single PR piece from ONCS about any conference they have attended this month. If anyone has please post it . Thanks

    Sentiment: Strong Buy

  • 3:02 pm pSivida presents preclinical data demonstrating sustained release of Avastin using Tethadur at ARVO Annual Meeting; says 'we believe the release rate of antibodies loaded into Tethadur can be controlled, which could permit sustained delivery of antibodies that currently must be delivered by frequent injections' (PSDV) :

    Co announced that it presented the first peer-reviewed preclinical data demonstrating the use of pSivida's Tethadur technology to provide sustained release of Avastin at the 14th Annual Meeting of ARVO (Association for Research in Vision and Ophthalmology).
    pSivida's Dinesh K. Nadarassan presented a poster entitled "Sustained Release of Bevacizumab (Avastin) from BioSilicon". The data from preclinical studies conducted by pSivida concluded that long-term sustained release of antibodies such as Avastin is achievable with Tethadur, a form of pSivida's BioSilicon technology, and that the release of the antibodies is controllable over a wide range by adjusting the pore size and surface area of Tethadur.
    "The implications of the ability to control the duration of sustained delivery of antibodies through pore size are significant. By varying pore size, we believe the release rate of antibodies loaded into Tethadur can be controlled, which could permit sustained delivery of antibodies that currently must be delivered by frequent injections

  • Reply to

    "RHHBY"

    by deltavit Apr 9, 2014 3:49 PM

    I am not understanding you. RHHBY has about a 20% higher Market Cap. Dividend payments go back since Noah sailed the ark

    Sentiment: Strong Buy

  • UNRIVALED AND PROVEN trial results demonstrate that Cesca Therapeutics (KOOL) is the most advanced Regenerative Medicine Stem Cell Therapeutics Company.

    These results are historical in any field of medicine.

    Cesca therapeutics recently announced record shattering clinical trial results from their 17 patient CLI trial:
    Highlights
    Before treatment, 100% of “No Option” patients required amputation
    12 months after treatment, 82.4% of patients had no amputation
    Pain level before treatment on a scale of 0 to 10 was SEVERE at 7.8
    Pain level 12 months after treatment was ALMOST NON-EXISTENT at 0.2
    6-minute walking distance before treatment was 14.5 meters
    6-minute walking distance 12 months after treatment was 157meters
    Before treatment, 11 patients had gangrene with or without ulceration
    12 months after treatment 0 patients had gangrene or ulceration
    NEW BLOOD VESSELS WERE REGENERATED AFTER TREATMENT.
    THERE WERE NO ADVERSE SIDE EFFECTS.
    MORE FACTS:

    CESCA’s AMI, Bone Union and Bone Marrow Stem Cell Transplant studies all show similar successes that are well advanced beyond peers

    CESCA shares are trading at less than $2.00 per share.

    If CESCA was trading at ONLY the AVERAGE MARKET CAP of their competitors, CESCA would be selling at $14.21 per share today.

    Sentiment: Strong Buy

  • "Rhhby" and "NVS" are related to each other in pharma. Why the "RHHBY" stock is acting so sluggish,especially compared to "NVS" ? Is it because of upcoming dividend payment ? If you share your
    insight, I will appreciate

  • I am sure these are silly questions but I am a pretty novice investor, anyway here goes:

    What is with the huge drop end of Feb this year 76 to 36? I didn't see any news of a split?

    Is it a concern that there is only 1% institution ownership? Does this have to do with it is an ADR?

    TIA

  • Zybrestat(r) in combination with roche avastin(r) trial achieves primary efficacy endpoint of a statistically significant increase in progression-free survival‏

RHHBY
36.770.00(0.00%)Jul 28 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.